About Altasciences
Don’t Miss the Latest Altasciences News!
Angel Reyes Joins Altasciences as General Manager of CDMO Services
Altasciences is pleased to welcome Angel Reyes as General Manager, Contract Development and Manufacturing Organization (CDMO) Services. Having previously been the Director of Operations at Catalent, he brings to Altasciences over a decade of experience in management and supervisory roles.
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
The impressive 8,000-square-foot space, which includes a test material department, features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
IN OTHER NEWS…
Altasciences’ Marie-Hélène Raigneau and Steve Mason Named Most Influential COOs in the Healthcare Industry to Follow in 2023
In honor of this recognition, Insights Care published two in-depth interviews with Altasciences’ Co-chief Operating Officers, providing a glimpse into their daily roles, their journeys to becoming part of Altasciences, and their thoughts on the industry.
• Read Marie-Hélène’s interview
• Read Steve Mason’s interview
View more Altasciences news on our website.
It's Been a Minute, See What You Missed! Top 10 Life Science Resources
| ||||||||||||
|
Getting to the Heart of Science With Natasha Savoie
Natasha Savoie, Senior Director of Quality Assurance at Altasciences, has an undeniable passion for science, a passion that drives her to ensure that the data we generate for our clients is reliable and precise.
Watch this video to experience Natasha's unwavering dedication to science.
![](/sites/default/files/inline-images/Natasha%20Savoie_LDS_Thumbnail_1280x780.jpg)
Hot off the Press!
| |||||||
Copyright © 2023, Altasciences, All rights reserved. |
Save Time. Choose the Right Regulatory Pathway.
Advantages of Conducting Early Phase Clinical Research in Canada
Given the regulatory constraints in Europe, Altasciences' Montréal facility continues to be an ideal choice for clinical research. Discover the benefits of conducting early phase research in Canada, such as time and cost savings.
![Advantages of Conducting Early Phase Clinical Research in Canada](https://news.altasciences.com/l/942753/2023-08-25/mzzsg/942753/1692982725syuycDu0/Social_media_e_bulletin_The_Altascientist_issue31.jpg)
This issue of The Altascientist examines the advantages of conducting early phase clinical research in Canada, including 76 days in time savings, and a predictable regulatory review.
![Determining the right regulatory pathway for your drug](https://news.altasciences.com/l/942753/2023-08-25/mzzsn/942753/16929847804G5TZDJj/Social_Media_Webinar_EPR_SoMe_v4.jpg)
In this on-demand webinar, Leslie Dowling and Roland Jbeily walk you through different regulatory pathways available to safely get your drug to market as quickly as possible.
Altasciences’ Canadian clinical facility consists of seven Phase I units, at which we conduct over 100 trials every year. We support the full range of first-in-human studies, specialty studies, and therapeutic areas, such as ophthalmology, CNS, and substance abuse.
We can help get you into the clinic faster—schedule a chat today!
Take five minutes to explore these insightful resources:
Podcast: The Benefits of Conducting a Clinical Trial in Canada
Drug Development Timelines: How Health Canada’s 30-Day Regulatory Review Process Could Provide an Advantage
Altasciences' Facilities: Moving in Unison
Medhealth Outlook: Altasciences—The Most Powerful and Integrated CRO/CDMO Solution
Thank You, From Altasciences
On June 15, our team took time to celebrate Altasciences, and how we move in unison to help you bring better drugs to the people who need them, faster.
Every day, and especially on Altasciences Day, I feel a great sense of appreciation and gratitude—for our talented experts who help build our business, as well as for YOUR ongoing trust and partnership.
Together, we change lives. And I can’t thank you enough for taking us along on your innovative, life-saving journey.
It is with pride that I share with you a photo album from our Altasciences Day celebrations.
Thank you again,
Chris Perkin
CEO, Altasciences
TOP 5 WAYS INTEGRATED DRUG DEVELOPMENT SOLUTIONS SAVE YOU TIME AND MONEY
Since 2004, the average cost of bringing a new drug to market has increased from $800 million to about $2.6 billion, without, for the most part, shorter development time
Volume On—Latest Scientific Audiobook Releases
Listen to the Latest Scientific Audiobook Releases
Delve deeper into the critical processes behind early phase drug development with audio versions of eBooks and The Altascientist, written by our experts with you in mind:
![]() The Altascientist: Issue 30 — The Evolution and Advancement of LCMS in Drug Development |
![]() The Altascientist: Issue 28 — Applications of Liquid-Filled, Hard-Shell Capsules in Drug Development |
![]() The Altascientist: Issue 29 — Building Your Early Phase Clinical Trial Data, From Protocol to Regulatory Submission |
![]() eBook: First-in-Human Solution for Small and Large Molecules |